ANVS

Annovis Bio Inc

1.13

Oct 30 • 3:59 PM ET +0.11 (10.78%)

1.12

Aftermarket • 7:59 PM ET -0.01 (-0.57%)

Healthcare Biotechnology USA Nano NYSE

Oct 30, 5:05 PMAnnovis Bio receives NYSE continued listing notice for failing $50M market cap and stockholders’ equity requirements

Peers: CGTX CRVO INMB AVXL ATHE ABOS PMN ACIU ALZN PRTA

| Held by: VTI VXF IWC BUSM

Scroll to Statements

Index	-
Market Cap	48.23M
Enterprise Value	29.50M
Income	-49.52M
Sales	0.00M
Book/sh	-0.10
Cash/sh	0.44
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Jan 29, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	2.58
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.47
Current Ratio	3.47
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.79
EPS next Y	-0.97
EPS next Q	-0.30
EPS this Y	-0.48%
EPS next Y	31.04%
EPS next 5Y	-2.67%
EPS past 3/5Y	23.23% -10.15%
Sales past 3/5Y	- -
EPS Y/Y TTM	11.96%
Sales Y/Y TTM	-
EPS Q/Q	-23.75%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	11.76% -

Insider Own	11.79%
Insider Trans	1.54%
Inst Own	31.42%
Inst Trans	4.86%
ROA	-227.74%
ROE	-703.68%
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	6.14%
SMA50	-10.18%
SMA200	-41.01%
Trades

Shs Outstand	42.61M
Shs Float	37.65M
Short Float	15.19%
Short Ratio	6.51
Short Interest	5.72M
52W High	5.50 -79.45%
52W Low	0.93 21.57%
Volatility	8.39% 7.32%
ATR (14)	0.08
RSI (14)	51.67
Beta	1.34
Rel Volume	1.71
Avg Volume	878.35K
Volume	1,499,373

Perf Week	13.08%
Perf Month	-3.42%
Perf Quarter	-34.30%
Perf Half Y	-43.50%
Perf YTD	-67.34%
Perf Year	-45.67%
Perf 3Y	-86.13%
Perf 5Y	-95.74%
Perf 10Y	-
Recom	1.00
Target Price	10.50
Prev Close	1.02
Price	1.13
Change %	10.78%

Consensus

Strong Buy

Avg. Price Target

$10.50

Implied Upside

+829.2%

Analysts4incl. previous ratings

Rating Distribution3 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 08, 2026	Initiated	RRoth Capital	Buy	$8	+608.0%
Feb 10, 2025	Downgrade	DD. Boral Capital	Buy → Hold
Oct 25, 2024	Upgrade	MMaxim Group	Hold → Buy	$25	+2,112.4%
Dec 29, 2023	Initiated	CCanaccord Genuity	Buy	$36	+3,085.8%
Jul 07, 2021	Reiterated	MMaxim Group	Buy	$45 → $150	+13,174.3%

Oct-30-26 05:00PM	Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE (GlobeNewswire) +10.78%
Oct-29-26 08:00AM	Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026 (GlobeNewswire)
Oct-22-26 08:00AM	Annovis to Attend the CTAD 2026 with Three Presentations (GlobeNewswire)
Sep-23-26 08:00AM	Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease (GlobeNewswire)
Aug-25-26 08:00AM	Annovis to Host Corporate Update Webinar on September 2, 2026 (GlobeNewswire)
08:00AM	Loading…
Aug-14-26 08:00AM	Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-07-26 10:51AM	Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial (NYSE)
07:00AM	Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease (GlobeNewswire)
Jul-01-26 08:00AM	Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer (GlobeNewswire)
May-26-26 08:00AM	Annovis Bio Regains NYSE Listing Compliance (GlobeNewswire) -7.62%
May-20-26 08:00AM	Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants (GlobeNewswire) +5.15%
May-19-26 04:06PM	Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants (GlobeNewswire) -5.37%
May-15-26 07:30AM	Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-07-26 07:30AM	Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026 (GlobeNewswire) -5.83%
Apr-28-26 08:00AM	Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio (GlobeNewswire)
08:30AM	Loading…
Apr-10-26 08:30AM	Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission (GlobeNewswire)
Apr-09-26 08:30AM	Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants (GlobeNewswire) -29.57%
Apr-02-26 07:30AM	Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections (GlobeNewswire) +7.55%
Mar-31-26 08:00AM	Annovis Publishes Historical Review of Buntanetap in The Scientist (GlobeNewswire) +10.95%
Mar-19-26 07:30AM	Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study (GlobeNewswire) +8.10%
Mar-16-26 07:30AM	Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results (GlobeNewswire) +12.30%
Mar-03-26 08:00AM	Annovis Announces Two Presentations at the AD/PD 2026 International Conference (GlobeNewswire)
Feb-12-26 08:00AM	Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease (GlobeNewswire)
Dec-18-25 04:35PM	Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients (GlobeNewswire)
Dec-16-25 08:00AM	Annovis to Host Corporate Update Webinar on January 28, 2026 (GlobeNewswire)
Dec-03-25 08:00AM	Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group (GlobeNewswire) +5.44%
Nov-24-25 08:00AM	Annovis Announces Two Presentations at the CTAD 2025 Conference (GlobeNewswire) +7.92%
Nov-18-25 08:00AM	Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study (GlobeNewswire) +11.22%
Nov-17-25 08:00AM	Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients (GlobeNewswire) +29.49%
Nov-12-25 08:00AM	Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results (GlobeNewswire) +15.17%
08:00AM	Loading…
Nov-06-25 08:00AM	Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program (GlobeNewswire)
Oct-27-25 08:00AM	Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules (GlobeNewswire)
Oct-15-25 05:15PM	Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock (GlobeNewswire) +7.74% +12.15%
Oct-10-25 08:31AM	Annovis Announces $6 Million Registered Direct Offering of Common Stock (GlobeNewswire) -22.73%
Oct-09-25 07:30AM	Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment (GlobeNewswire)
Sep-25-25 07:30AM	Annovis Appoints Mark Guerin as Chief Financial Officer (GlobeNewswire)
Sep-16-25 07:30AM	Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap (GlobeNewswire)
Sep-02-25 08:00AM	Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-29-25 07:24AM	Annovis (ANVS) Secures Patent Coverage for Both Forms of Buntanetap (Insider Monkey)
Aug-12-25 04:05PM	Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-07-25 08:00AM	Annovis Completes Full Patent Transfer to Crystal Buntanetap (GlobeNewswire)
Jun-26-25 08:00AM	Annovis to Attend the AAIC 2025 with Four Poster Presentations (GlobeNewswire) -5.24%
Jun-19-25 06:30AM	Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance (GlobeNewswire)
Jun-11-25 12:00PM	All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy (Zacks)
Jun-05-25 08:00AM	Annovis to Host Webinar and Live Q&A on June 24, 2025 (GlobeNewswire) -5.86%
May-13-25 04:30PM	Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results (GlobeNewswire) +9.68%
Apr-29-25 08:00AM	Annovis Bio Appoints Hui Liu as Director of Biostatistics (GlobeNewswire) -5.16%
Mar-27-25 04:30PM	Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE (GlobeNewswire) -10.81%
Mar-25-25 08:00AM	Annovis to Attend AD/PD 2025 with Extensive Scientific Program (GlobeNewswire) +6.49%
Mar-21-25 05:05PM	Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results (GlobeNewswire) +5.71%
Mar-11-25 08:00AM	Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment (GlobeNewswire)
Feb-19-25 08:30AM	Annovis to Host Patients' Live Forum on February 27, 2025 (GlobeNewswire) -6.85%
Feb-07-25 08:00AM	Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-06-25 11:21AM	Annovis begins treatment of subjects in Alzheimers trial (Clinical Trials Arena)
08:20AM	Annovis Bio announces first patients entered Phase 3 study of buntanetap (TipRanks)
Feb-05-25 08:00AM	Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease (GlobeNewswire)
Feb-04-25 04:31PM	Annovis Bio, Inc. Announces Closing of $21 Million Public Offering (GlobeNewswire)
Feb-03-25 06:22AM	Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering (GlobeNewswire) -33.47%
Jan-31-25 08:14PM	Annovis Bio, Inc. Announces Proposed Public Offering (GlobeNewswire)
Jan-15-25 08:11AM	Annovis Bio granted U.S. patent covering buntanetap (TipRanks)
Jan-14-25 08:00AM	Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection (GlobeNewswire)
Jan-07-25 08:00AM	FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer's Disease Study, Streamlining Development Pathway (GlobeNewswire) -5.61%
Dec-05-24 08:30AM	Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace (GlobeNewswire)
Dec-04-24 02:21PM	Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace (PR Newswire) -6.42%
Nov-25-24 08:00AM	Annovis to Host Year-End Investor Webcast on December 11, 2024 (GlobeNewswire) +6.32%
Nov-12-24 08:00AM	Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) (GlobeNewswire)
Nov-11-24 08:00AM	Annovis Bio Reports Third Quarter Financial Results and Provides Business Update (GlobeNewswire) -6.25%
Nov-07-24 08:00AM	Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist (GlobeNewswire)
Oct-31-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio (GlobeNewswire)
Oct-22-24 08:00AM	Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 (GlobeNewswire)
Oct-17-24 10:52AM	Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug (GuruFocus.com) -5.25%
Oct-15-24 08:00AM	FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs (GlobeNewswire) +6.26%
Oct-03-24 08:30AM	Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More (PR Newswire)
08:30AM	Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases (GlobeNewswire)
Oct-02-24 08:30AM	Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations (GlobeNewswire) +5.42%
Sep-30-24 08:00AM	Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra (GlobeNewswire)
Sep-05-24 08:00AM	Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.76%
Aug-15-24 07:00AM	Annovis Bio Reports Second Quarter Financial Results and Provides Business Update (GlobeNewswire) +14.05%
Aug-06-24 09:00AM	Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities (GlobeNewswire)
08:30AM	Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033 (GlobeNewswire)
08:00AM	Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist (GlobeNewswire)
Aug-05-24 08:00AM	IBN Announces Latest Episode of The Bell2Bell Podcast Featuring Annovis Bio CEO Dr. Maria Maccecchini, Live from AAIC 2024 (GlobeNewswire)
Jul-24-24 08:00AM	Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap (GlobeNewswire)
Jul-16-24 08:00AM	Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap (GlobeNewswire)
Jul-09-24 08:00AM	Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team (GlobeNewswire) -5.76%
Jul-03-24 12:53PM	Annovis stock swells after Phase III Parkinsons subgroup success (Clinical Trials Arena) -12.93%
12:21PM	Annovis Bio shares dip on phase III Parkinson's trial data (Yahoo Finance Video)
09:10AM	Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study (Zacks)
Jul-02-24 04:45PM	Why Did Annovis Bio (ANVS) Stock Close Up 80% Today? (InvestorPlace) +76.09%
08:00AM	Annovis Bio Announces New Data from Phase III Parkinson's Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap (GlobeNewswire)
Jun-27-24 08:00AM	Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap (GlobeNewswire)
Jun-26-24 08:00AM	Annovis Bio Files Patent for New Composition of Matter for Buntanetap (GlobeNewswire)
Jun-25-24 08:00AM	Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson's Disease Data (GlobeNewswire) -8.70%
Jun-18-24 08:00AM	Annovis Bio Highlights New Alzheimer's Data at the Alzheimer's Association International Conference 2024 (GlobeNewswire)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE) -5.81%
Jun-11-24 08:00AM	Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients (GlobeNewswire)
Jun-05-24 08:00AM	Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast (GlobeNewswire)
May-28-24 09:55AM	Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet (Zacks) -8.78%
May-21-24 07:30AM	Annovis Announces New Publication in a Peer-Reviewed Journal (GlobeNewswire) -5.94%
May-13-24 01:53PM	ANVS Stock Earnings: Annovis Bio Beats EPS for Q1 2024 (InvestorPlace) +15.51%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hoffman Michael B	Director	May 20 '26	Buy	1.87	76,344	142,779	3,364,883	May 21 08:11 PM
Hoffman Michael B	Director	Apr 02 '26	Buy	2.10	713,800	1,498,980	3,288,539	Apr 03 05:06 PM
White Mark K.	Director	Apr 02 '26	Proposed Sale	2.08	7,142	14,848		Apr 02 04:39 PM
Hoffman Michael B	Director	Dec 08 '25	Buy	4.31	45,000	193,794	2,574,739	Dec 08 08:05 PM
Hoffman Michael B	Director	Nov 24 '25	Buy	4.08	39,200	159,886	2,519,739	Nov 25 12:26 PM
Hoffman Michael B	Director	Nov 21 '25	Buy	3.50	20,000	69,900	2,490,539	Nov 21 07:57 PM
Hoffman Michael B	Director	Nov 14 '25	Buy	2.11	15,000	31,650	2,470,539	Nov 18 07:44 AM

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

FounderDr. Maria L. Maccecchini Ph.D.

Chief Scientific OfficerDr. Cheng Fang Ph.D.

RACMs. Eve M. Damiano M.S.

Head of QualityMr. Blake Jensen M.B.A.

Senior Vice President of StatisticsMs. Hilda Maibach

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANVS

Annovis Bio Inc

Upgrade your Finviz experience